Added to YB: 2025-08-05
Pitch date: 2025-08-03
ABBV [neutral]
AbbVie Inc.
+7.72%
current return
Author Info
Disruptive Analytics has 30+ years of experience as a retail investor and is now fully engaged in managing their own money. Sign up for the newsletter.
Company Info
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide.
Market Cap
$369.4B
Pitch Price
$191.87
Price Target
220.00 (+6%)
Dividend
3.31%
EV/EBITDA
14.59
P/E
88.49
EV/Sales
7.07
Sector
Biotechnology
Category
growth
Two wins and one loss - AbbVie Inc.
ABBV (earnings update - increased position): Strong Q2 with guidance raised again. Skyrizi/Rinvoq (arthritis) growing rapidly, neuroscience (Botox) gaining, oncology launching well but from small base. Goldman raised PT to $217, Morgan Stanley to $255. Fair value ~$220. Position increased from 3% to 4% of portfolio while NOVO reduced from 7% to 3%.
Read full article (1 min)